Comparison of the effects of Sertindole and Olanzapine on Cognition (SEROLA): A double-blind randomized 12-week study of patients diagnosed with schizophrenia

Therapeutic Advances in Psychopharmacology

Volumn 4, Issue 1, 2014, Pages 4-14

  Ernst Nielsen, René ^a   Odur, Florence ^b   Østergaard, Torben ^c   Munk Jørgensen, Povl ^d   Nielsen, Jimmi ^c  

^a Aalborg Psykiatriske Sygehus   (Denmark)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

cognition; olanzapine; randomized controlled trial; schizophrenia; sertindole

Indexed keywords

EID: 84997860279     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125313499065     Document Type: Article

References (31)

1. Addington D. Addington J. Maticka-Tyndale E. (1994) Specificity of the Calgary Depression Scale for Schizophrenics. Schizophr Res 11: 239–244.
2. Addington D. Addington J. Maticka-Tyndale E. Joyce J. (1992) Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6: 201–208.
3. Buchanan R. Davis M. Goff D. Green M. Keefe R. Leon A. et al. (2005) A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 31: 5–19.
4. Cannon T. Zorrilla L. Shtasel D. Gur R. Gur R. Marco E. et al. (1994) Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry 51: 651–661.
5. Caspi A. Reichenberg A. Weiser M. Rabinowitz J. Kaplan Z. Knobler H. et al. (2003) Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res 65: 87–94.
6. Citrome L. Holt R. Walker D. Hoffmann V. (2011) Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig 31: 455–482.
7. Correll C. (2010) From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 25(Suppl. 2): S12–S21.
8. Desmarais J. Beauclair L. Margolese H. (2012) Anticholinergics in the era of atypical antipsychotics: Short-term or long-term treatment? J Psychopharmacol 26: 1167–1174.
9. Fagerlund B. Soholm B. Fink-Jensen A. Lublin H. Glenthoj B. (2007) Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol 30: 3–12.
10. Freedman R. Olincy A. Buchanan R. Harris J. Gold J. Johnson L. et al. (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165: 1040–1047.
11. Gallhofer B. Jaanson P. Mittoux A. Tanghoj P. Lis S. Krieger S. (2007) Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 40: 275–286.
12. Kay S. Fiszbein A. Opler L. (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.
13. Kay S. Opler L. Spitzer R. Williams J. Fiszbein A. Gorelick A. (1991) SCID-PANSS: two-tier diagnostic system for psychotic disorders. Compr Psychiatry 32: 355–361.
14. Keefe R. Bilder R. Davis S. Harvey P. Palmer B. Gold J. et al. (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64: 633–647.
15. Levander S. Jensen J. Grawe R. Tuninger E. (2001) Schizophrenia – progressive and massive decline in response readiness by episodes. Acta Psychiatr Scand (Suppl. 408): 65–74.
16. Lowe C. Rabbitt P. (1998) Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge Neuropsychological Test Automated Battery. International Study of Post-operative Cognitive Dysfunction. Neuropsychologia 36: 915–923.
17. McGurk S. Green M. Wirshing W. Wirshing D. Marder S. Mintz J. et al. (2004) Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr Res 68: 225–233.
18. Minzenberg M. Poole J. Benton C. Vinogradov S. (2004) Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 161: 116–124.
19. Nielsen R. (2011) Cognition in schizophrenia – a systematic review. Drug Discov Today: Ther Strategies 8: 43–48.
20. Nielsen R. Levander S. Thode D. Nielsen J. (2012) Effects of sertindole on cognition in clozapine-treated schizophrenia patients. Acta Psychiatr Scand 126: 31–39.
21. Nielsen R. Nielsen J. (2009) Antipsychotic drug treatment for patients with schizophrenia. Clin Med Ther 1: 1053–1068.
22. Pae C. (2013) Role of the cholinesterase inhibitors in the treatment of schizophrenia. Expert Opin Investig Drugs 22: 293–298.
23. Peuskens J. Tanghoj P. Mittoux A. (2008) The sertindole cohort prospective (SCoP) study: rationale, design and methodology. Pharmacoepidemiol Drug Saf 17: 425–433.
24. Rund B. (2009) Is schizophrenia a neurodegenerative disorder? Nord J Psychiatry 63: 196–201.
25. Sahakian B. Owen A. (1992) Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med 85: 399–402.
26. Seeman P. Tallerico T. (1998) Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3: 123–134.
27. Shekhar A. Potter W. Lightfoot J. Lienemann J. Dube S. Mallinckrodt C. et al. (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165: 1033–1039.
28. Szoke A. Trandafir A. Dupont M. Meary A. Schurhoff F. Leboyer M. (2008) Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 192: 248–257.
29. Tracy J. Monaco C. Abraham G. Josiassen R. Pollock B. (1998) Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J Clin Psychiatry 59: 184–188.
30. Wallace T. Ballard T. Pouzet B. Riedel W. Wettstein J. (2011) Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav 99: 130–145.
31. World Health Organization (1992) ICD-10 Classifications of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization.